OTC Markets OTCQB - Delayed Quote USD

BioCorRx Inc. (BICX)

Compare
0.3000 0.0000 (0.00%)
At close: October 25 at 4:00 PM EDT
Loading Chart for BICX
DELL
  • Previous Close 0.0000
  • Open 0.3000
  • Bid 0.3000 x --
  • Ask 0.4995 x --
  • Day's Range 0.3000 - 0.3000
  • 52 Week Range 0.2820 - 1.6100
  • Volume 162
  • Avg. Volume 667
  • Market Cap (intraday) 3.267M
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4800
  • Earnings Date Aug 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program for substance abuse that includes peer recovery support; and distributes UnCraveRx weight loss management program, a medically assisted weight management program. The company is also developing BICX101, an injectable and implantable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

www.biocorrx.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BICX

View More

Performance Overview: BICX

Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BICX
61.54%
S&P 500
21.77%

1-Year Return

BICX
81.37%
S&P 500
36.74%

3-Year Return

BICX
92.00%
S&P 500
27.79%

5-Year Return

BICX
90.00%
S&P 500
92.94%

Compare To: BICX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BICX

View More

Valuation Measures

Annual
As of 10/25/2024
  • Market Cap

    3.27M

  • Enterprise Value

    5.44M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    72.22

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    147.94

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -417.17%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    36.75k

  • Net Income Avi to Common (ttm)

    -4.29M

  • Diluted EPS (ttm)

    -0.4800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.37k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -599.07k

Research Analysis: BICX

View More

Company Insights: BICX

Research Reports: BICX

View More

People Also Watch